Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
Cancer Cell. 2011 Dec 13;20(6):728-40. doi: 10.1016/j.ccr.2011.11.006. Epub 2011 Dec 1.
We report that diffuse large B cell lymphoma (DLBCL) commonly fails to express cell-surface molecules necessary for the recognition of tumor cells by immune-effector cells. In 29% of cases, mutations and deletions inactivate the β2-Microglobulin gene, thus preventing the cell-surface expression of the HLA class-I (HLA-I) complex that is necessary for recognition by CD8(+) cytotoxic T cells. In 21% of cases, analogous lesions involve the CD58 gene, which encodes a molecule involved in T and natural killer cell-mediated responses. In addition to gene inactivation, alternative mechanisms lead to aberrant expression of HLA-I and CD58 in >60% of DLBCL. These two events are significantly associated in this disease, suggesting that they are coselected during lymphomagenesis for their combined role in escape from immune-surveillance.
我们报告称,弥漫性大 B 细胞淋巴瘤(DLBCL)通常无法表达免疫效应细胞识别肿瘤细胞所需的细胞表面分子。在 29%的病例中,β2-微球蛋白基因的突变和缺失会使 HLA Ⅰ类(HLA-I)复合物的细胞表面表达失活,而该复合物对于 CD8(+)细胞毒性 T 细胞的识别是必需的。在 21%的病例中,类似的病变涉及 CD58 基因,该基因编码一种参与 T 细胞和自然杀伤细胞介导反应的分子。除了基因失活外,在超过 60%的 DLBCL 中,还存在导致 HLA-I 和 CD58 异常表达的其他机制。这两种事件在这种疾病中显著相关,表明它们在淋巴瘤发生过程中因共同作用于逃避免疫监视而被共同选择。